Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Inclusion criteria

• Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject).
• Nonsmoker
• Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
• Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
• If female and of childbearing potential and subjects agrees to employ adequate birth control measures (e. g. oral contraceptives, barrier method)
• Negative urine pregnancy test

Exclusion criteria

• Known or suspected allergy to trial product or related products
• Pregnancy or Lactation
• Treatment with an investigational drug within three weeks prior to this trial
• Participation in an LPS trial within the last 6 weeks
• Smoking
• History of relevant cardiac arrhythmia
• Preexisting open or closed angle glaucoma
• History of Osteoporosis, Cushing´s syndrome, gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, hypertension, brain tumor or history of neurosurgery
• Systemic tuberculosis
• Hemorrhagic diathesis
• Relevant liver or kidney dysfunction
• Regular use of medication or abuse of alcohol unless considered clinically relevant
• Use of any medication within one week prior to the first trial day
• Symptoms of a clinically relevant illness in the 3 weeks before the first trial day
• Excessive sporting activities
• Rosacea
• Subjects on Monoamine oxidase inhibitors (should be stopped for at least two to three weeks before dihydrocodeine treatment is initiate)
• Known acute or active hepatic disease within the past 3 months
• A platelet count < 100,000 x 106/L, prothrombin time > 1.5, liver enzymes> 3 times the upper normal limit
• Having received a vaccination up to 8 weeks before the trial